Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g.， pregabalin， duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT)， noradrenaline (NE)， and dopamine (DA) play important roles in modulating the descending inhibitory pain pathway and sleep-wake cycle. The aim of this work was to test the hypothesis that LPM580098， a novel triple reuptake inhibitor (TRI) of 5-HT， NE， and DA， has analgesic effect， and does not induce significant adverse effects associated with central inhibition， such as sedation and somnolence. The analgesic activity of LPM580098 was assessed on formalin test and spinal nerve ligation (SNL)-induced neuropathic pain model. Locomotor activity， pentobarbital sodium-induced sleeping and rota-rod tests were also conducted. binding and uptake assays， and Western blotting were performed to examine the potential mechanisms. LPM580098 suppressed the nocifensive behaviors during phase II of the formalin test in mice. In SNL rats， LPM580098 (16 mg kg) inhibited mechanical allodynia， thermal hyperalgesia and hyperexcitation of wide-dynamic range (WDR) neurons， in which the effect of LPM580098 was similar to pregabalin (30 mg kg). However， pregabalin altered the spontaneous locomotion， affected pentobarbital sodium-induced sleep， and showed a trend to perform motor dysfunction， which were not induced by LPM580098. Mechanistically， LPM580098 inhibited the uptake of 5-HT， NE， and DA， improved pain-induced changes of the synaptic functional plasticity and structural plasticity possibly via downregulating the NR2B/CaMKIIα/GluR1 and Rac1/RhoA signaling pathways. Our results suggest that LPM580098， a novel TRI， is effective in attenuating neuropathic pain without producing unwanted sedation and somnolence associated with central nervous system (CNS) depressants.